Evidence map›Paper›PMID 29976590›Full record

ArticleJournal of clinical microbiology2018

Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.

Adam L Bailey, Tom Armstrong, Hari-Prakash Dwivedi, Gerald A Denys, Janet Hindler, Shelley Campeau, Maria Traczewski, Romney Humphries, C A Burnham

Open access · bronzeAbstract readComparative StudyEvaluation StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Emerging Carbapenem-ResistantInfection and drug resistance · 2021
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Adam L BaileyDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Tom ArmstrongbioMérieux Inc., Hazelwood, Missouri, USA.
Hari-Prakash DwivedibioMérieux Inc., Hazelwood, Missouri, USA.
Gerald A DenysIndiana University School of Medicine, Indianapolis, Indiana, USA.
Janet HindlerDepartment of Pathology and Laboratory Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Shelley CampeauDepartment of Pathology and Laboratory Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Maria TraczewskiClinical Microbiology Institute, Inc., Wilsonville, Oregon, USA.
Romney HumphriesDepartment of Pathology and Laboratory Medicine, University of California-Los Angeles, Los Angeles, California, USA.
C A BurnhamDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA cburnham@wustl.edu.ORCID 0000-0002-1137-840X
University of California, Los Angeles · USbioMérieux (United States) · USWashington University in St. Louis · USHuman BioMolecular Research Institute · USIndiana University School of Medicine

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ceftolozane-tazobactam (C/T) is a novel beta-lactam-beta-lactamase inhibitor combination antibiotic approved by the U.S. Food and Drug Administration in 2014 for the treatment of complicated intra-abdominal infections (in combination with metronidazole) and complicated urinary tract infections. In this study, we evaluated the performance of the C/T Etest, a gradient diffusion method. C/T Etest was compared to broth microdilution (BMD) for 51

Indexed as

Anti-Bacterial AgentsCephalosporinsDisk Diffusion Antimicrobial TestsDrug Resistance, Multiple, BacterialEnterobacteriaceaeEnterobacteriaceae InfectionsHumansPseudomonas aeruginosaPseudomonas InfectionsReproducibility of ResultsTazobactamAnti-Bacterial Agentsceftolozane, tazobactam drug combinationCephalosporinsTazobactamantimicrobial susceptibility testingceftolozane-tazobactamEnterobacteriaceaeEtestgradient diffusion methodPseudomonas aeruginosa

Identifiers

PMID29976590
PMCPMC6113460
OpenAlexW2809705979

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.